4//SEC Filing
Krishnan Krish S 4
Accession 0001298709-25-000013
CIK 0001711279other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 6:53 PM ET
Size
38.6 KB
Accession
0001298709-25-000013
Insider Transaction Report
Form 4
Krishnan Krish S
DirectorPresident and CEO10% Owner
Transactions
- Sale
Common Stock
2025-12-04$214.28/sh−956$204,851→ 1,507,100 total - Sale
Common Stock
2025-12-04$215.48/sh−344$74,126→ 1,506,756 total - Sale
Common Stock
2025-12-04$217.04/sh−1,600$347,272→ 1,505,156 total - Sale
Common Stock
2025-12-04$218.72/sh−2,577$563,638→ 1,502,579 total - Sale
Common Stock
2025-12-04$219.55/sh−5,693$1,249,917→ 1,496,886 total - Sale
Common Stock
2025-12-04$220.34/sh−2,625$578,395→ 1,494,261 total - Sale
Common Stock
2025-12-04$221.78/sh−10,505$2,329,772→ 1,483,756 total - Sale
Common Stock
2025-12-04$222.20/sh−700$155,539→ 1,483,056 total - Gift
Common Stock
2025-12-05−5,000→ 1,478,056 total - Sale
Common Stock
2025-12-04$215.49/sh−600$129,296→ 1,437,411 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$216.97/sh−1,400$303,754→ 1,436,011 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$218.83/sh−3,593$786,245→ 1,432,418 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$219.68/sh−5,419$1,190,423→ 1,426,999 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$220.52/sh−2,627$579,301→ 1,424,372 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$221.82/sh−10,461$2,320,471→ 1,413,911 total(indirect: By Spouse) - Sale
Common Stock
2025-12-04$222.38/sh−200$44,475→ 1,413,711 total(indirect: By Spouse)
Holdings
- 90,000(indirect: By Trust)
Common Stock
- 50,000(indirect: By Trust)
Common Stock
Footnotes (21)
- [F1]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan.
- [F10]Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund.
- [F11]Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
- [F12]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan.
- [F13]The transaction was executed in multiple trades ranging from $213.87 to $214.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F14]Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.
- [F15]The transaction was executed in multiple trades ranging from $215.34 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F16]The transaction was executed in multiple trades ranging from $216.60 to $217.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F17]The transaction was executed in multiple trades ranging from $218.21 to $219.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F18]The transaction was executed in multiple trades ranging from $219.21 to $220.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F19]The transaction was executed in multiple trades ranging from $220.21 to $221.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F2]The transaction was executed in multiple trades ranging from $213.93 to $214.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F20]The transaction was executed in multiple trades ranging from $221.21 to $222.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F21]The transaction was executed in multiple trades ranging from $222.34 to $222.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $214.99 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The transaction was executed in multiple trades ranging from $216.73 to $217.63. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The transaction was executed in multiple trades ranging from $218.11 to $219.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The transaction was executed in multiple trades ranging from $219.14 to $220.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F7]The transaction was executed in multiple trades ranging from $220.14 to $221.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F8]The transaction was executed in multiple trades ranging from $221.14 to $222.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F9]The transaction was executed in multiple trades ranging from $222.14 to $222.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Documents
Issuer
Krystal Biotech, Inc.
CIK 0001711279
Entity typeother
Related Parties
1- filerCIK 0001298709
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 6:53 PM ET
- Size
- 38.6 KB